MRI BIOMARKERS OF ANGIOGENESIS AND CELL INJURY IN RETINOPATHY OF PREMATURITY
MRI BIOMARKERS OF ANGIOGENESIS AND CELL INJURY IN RETINOPATHY OF PREMATURITY
批准号:
7577530
负责人:
Junjie Chen
金额:
$19.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2010-02-28
关键词:
Acetic AcidsAdultAdverse effectsAreaBindingBiological MarkersBlindnessCell HypoxiaCellsChildCorneaDiagnostic ProcedureDiffusionDiffusion Magnetic Resonance ImagingDisease MarkerDisease ProgressionEarly DiagnosisFluorocarbonsGadoliniumHyperglycemiaHypoxiaImaging TechniquesIntegrinsLeadMagnetic ResonanceMagnetic Resonance ImagingMalignant - descriptorMeasuresMedicalMedical ImagingMethodsModelingMolecularNeonatalOperative Surgical ProceduresOryctolagus cuniculusOxygenOxygen ConsumptionPathologic NeovascularizationPatientsPentasPeripheralPharmaceutical PreparationsPhotoreceptorsPremature InfantPreventiveRattusResearchResolutionRetinaRetinalRetinal DetachmentRetinal DiseasesRetinal NeovascularizationRetinopathy of PrematurityRodentSpecific qualifier valueSurfaceTechniquesTestingVisionVisual system structureWeightabstractingangiogenesisantiangiogenesis therapybasecell injurycostdiabeticdiethylenetriamineeffective therapyexperienceimaging modalityindexinginjuredinterestnanoparticleneovasculaturenovelnovel diagnosticsphotoreceptor degenerationpreventproliferative diabetic retinopathyretinal angiogenesisretinal ischemiatool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Proliferative retinopathy is a leading cause of blindness in adults and children. It is manifested as hypoxia induced malignant angiogenesis at retinal surface that will deteriorate vision and lead to retinal detachment to cause permanent vision loss. Medical therapy for proliferative retinopathy is non-effective. Surgical medical treatment to ablate peripheral retina is the method to prevent the disease progression at the cost of losing peripheral vision. This treatment has prominent side effects on the visual system and may not stop the disease progression in some patients. Current interests on developing more effective therapy for proliferative retinopathy are: to develop anti-angiogenesis drug that specifically inhibit retinal neovascularization; to explore predictive markers of the diseases for preventive therapy. We have developed high resolution magnetic resonance imaging (MRI) technique that specifies multiple retinal layers with layer specific T1, T2, and apparent diffusion coefficient (ADC) in rodents. Our preliminary studies have demonstrated that MRI is sensitive to cell injury after retinal ischemia or photoreceptor degeneration. We have also shown that 1v23-integrin targeted nanoparticles specifically bind to corneal neovasculature and provide localized MRI contrast in rabbits. Based on our preliminary result, we hypothesize that hypoxia induced retinal angiogenesis could be specifically delineated with molecular MRI using 1v23-integrin targeted nanoparticles. Hypoxia will also cause retinal cell injury that will result in changes in ADC before retinal angiogenesis. To test our hypothesis, a rat model of hypoxia induced retinal neovascularization is selected. We predict that 1v23-integrin targeted nanoparticles will specifically bind to retinal neovasculature for molecular MRI of retinal angiogenesis. We also expect changes in ADC in hypoxia injured retinal cells can be detected early with diffusion weighted magnetic resonance imaging. The proposed study, if successful, will provide novel MRI biomarkers for early diagnosis of retinal neovascularization that feature cell hypoxia and angiogenesis. PUBLIC HEALTH RELEVANCE: Retinal angiogenesis is the leading cause of blindness in premature infants and diabetic adults. The proposed research aims to develop techniques for early diagnosis of retinal angiogenesis using nanoparticles and non-invasive medical imaging method.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Deciphering pathways involved in topoisomerase II turnover
-
批准号:10552113
-
项目类别:
-
资助金额:$50.3万
-
财政年份:2023
-
负责人:Junjie Chen
-
依托单位:
Elucidating mechanisms underlying replication checkpoint control
-
批准号:10620981
-
项目类别:
-
资助金额:$49.94万
-
财政年份:2023
-
负责人:Junjie Chen
-
依托单位:
Exploring DNA damage response pathways as targets for cancer therapy
-
批准号:10515484
-
项目类别:
-
资助金额:$58.34万
-
财政年份:2022
-
负责人:Junjie Chen
-
依托单位:
Novel regulations of DNA damage repair
-
批准号:9883637
-
项目类别:
-
资助金额:$43.64万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Novel regulations of DNA damage repair
-
批准号:10087898
-
项目类别:
-
资助金额:$43.64万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Novel regulations of DNA damage repair
-
批准号:9326453
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Define redundant functions of H2AX and NBS1 in DNA repair
-
批准号:10311996
-
项目类别:
-
资助金额:$35.87万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Project 4: Coordinating Nucleolytic Pathways During Crosslink Repair
-
批准号:9148677
-
项目类别:
-
资助金额:$35.43万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Define redundant functions of H2AX and NBS1 in DNA repair
-
批准号:9206732
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Define redundant functions of H2AX and NBS1 in DNA repair
-
批准号:10053713
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
53BP1-dependent pathway in DNA repair
-
批准号:9763542
-
项目类别:
-
资助金额:$35.5万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
53BP1-dependent pathway in DNA repair
-
批准号:10404655
-
项目类别:
-
资助金额:$35.87万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Fanconi anemia pathway in DNA damage repair
-
批准号:8234219
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:Junjie Chen
-
依托单位:
Fanconi anemia pathway in DNA damage repair
-
批准号:8467691
-
项目类别:
-
资助金额:$30.82万
-
财政年份:2012
-
负责人:Junjie Chen
-
依托单位:
Fanconi anemia pathway in DNA damage repair
-
批准号:8628642
-
项目类别:
-
资助金额:$31.8万
-
财政年份:2012
-
负责人:Junjie Chen
-
依托单位:
Fanconi anemia pathway in DNA damage repair
-
批准号:8826053
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:Junjie Chen
-
依托单位:
MRI BIOMARKERS OF ANGIOGENESIS AND CELL INJURY IN RETINOPATHY OF PREMATURITY
-
批准号:7450075
-
项目类别:
-
资助金额:$21.76万
-
财政年份:2008
-
负责人:Junjie Chen
-
依托单位:
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast Cancer
-
批准号:7737070
-
项目类别:
-
资助金额:$20.67万
-
财政年份:2008
-
负责人:Junjie Chen
-
依托单位:
Study the Role of Chfr in Tumorigenesis
-
批准号:7806610
-
项目类别:
-
资助金额:$26.54万
-
财政年份:2006
-
负责人:Junjie Chen
-
依托单位:
Study the Role of Chfr in Tumorigenesis
-
批准号:8232694
-
项目类别:
-
资助金额:$27.23万
-
财政年份:2006
-
负责人:Junjie Chen
-
依托单位:
海外基金